{"id":12893,"date":"2023-07-06T15:39:22","date_gmt":"2023-07-06T19:39:22","guid":{"rendered":"https:\/\/afcomunicacion.com\/uncategorized\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/"},"modified":"2023-07-06T15:39:22","modified_gmt":"2023-07-06T19:39:22","slug":"cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk","status":"publish","type":"post","link":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/","title":{"rendered":"Cleveland Clinic-led trial shows cholesterol-lowering drug reduces cardiac events, including death, in statin-intolerant patients at high cardiovascular risk"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li><em>The patients had risk factors but no pre-existing heart disease.<\/em><\/li>\n<\/ul>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignleft size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Redujo-significativamente-la-posibilidad-de-muerte-por-enfermedad-cardiaca-1024x666.jpg\" alt=\"\" class=\"wp-image-8193\" width=\"353\" height=\"230\" srcset=\"https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Redujo-significativamente-la-posibilidad-de-muerte-por-enfermedad-cardiaca-1024x666.jpg 1024w, https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Redujo-significativamente-la-posibilidad-de-muerte-por-enfermedad-cardiaca-300x195.jpg 300w, https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Redujo-significativamente-la-posibilidad-de-muerte-por-enfermedad-cardiaca-768x499.jpg 768w, https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Redujo-significativamente-la-posibilidad-de-muerte-por-enfermedad-cardiaca-1536x998.jpg 1536w, https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Redujo-significativamente-la-posibilidad-de-muerte-por-enfermedad-cardiaca-2048x1331.jpg 2048w\" sizes=\"auto, (max-width: 353px) 100vw, 353px\" \/><\/figure>\n<\/div>\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\">Findings from a clinical trial led by <strong><mark style=\"color:#138c00\" class=\"has-inline-color\">Cleveland Clinic<\/mark><\/strong> showed that the use of <strong><mark style=\"color:#0b5d8c\" class=\"has-inline-color\">bempedoic acid (a cholesterol-lowering drug)<\/mark><\/strong> in statin-intolerant patients who have not yet had a cardiovascular event but have risk factors such as diabetes significantly reduced the chance of death from heart disease and other major adverse cardiovascular events, such as heart attacks and strokes.<\/p>\n\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\">The findings were presented during a late-breaking scientific session at the <strong><mark style=\"color:#0b5d8c\" class=\"has-inline-color\">American Diabetes Association&#8217;s 83rd Scientific Sessions in San Diego<\/mark><\/strong> and published simultaneously in the <strong><mark style=\"color:#0b5d8c\" class=\"has-inline-color\">Journal of the American Medical Association.<\/mark><\/strong><\/p>\n\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\">In March, results from the <em><strong><mark style=\"color:#0b5d8c\" class=\"has-inline-color\">CLEAR Outcomes<\/mark><\/strong><\/em> trial showed that <strong><mark style=\"color:#0b5d8c\" class=\"has-inline-color\"><strong><mark style=\"color:#0b5d8c\" class=\"has-inline-color\">bempedoic acid<\/mark><\/strong><\/mark><\/strong> reduced adverse cardiovascular outcomes in 14,000 statin-intolerant patients. Within the <strong><mark style=\"color:#0b5d8c\" class=\"has-inline-color\">CLEAR<\/mark><\/strong> trial, 4,200 enrolled patients were at high risk of heart disease but had no previous cardiovascular events (primary prevention). <\/p>\n\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\">After six months of treatment, <strong><mark style=\"color:#0b5d8c\" class=\"has-inline-color\">bempedoic acid<\/mark><\/strong>, compared with placebo, lowered LDL cholesterol by 23.2% and reduced inflammation as measured by C-reactive protein by 22.7%. In this primary prevention subgroup, there was also a 30% reduction in major cardiovascular events, a 39% reduction in death from heart disease and a 39% decrease in heart attacks.<\/p>\n\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\"><mark style=\"color:#138c00\" class=\"has-inline-color\">&#8220;These findings emphasise the major benefits of lipid-lowering therapy in patients without a previous cardiovascular event but who are at risk of a first event,&#8221;<\/mark> said the study&#8217;s lead author, <strong><mark style=\"color:#0b5d8c\" class=\"has-inline-color\">Dr. Steven E. Nissen, Chief Academic Officer of the Heart, Vascular &amp; Thoracic Institute at <\/mark><mark style=\"color:#138c00\" class=\"has-inline-color\">Cleveland Clinic.<\/mark><\/strong> &#8220;Approximately two-thirds of participants had diabetes, which further supports recommendations that primary prevention patients with diabetes should be treated with cholesterol-lowering therapies.&#8221;<\/p>\n\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\">Primary prevention patients are currently undertreated in the United States, and more than half of patients at high risk of a cardiovascular event are not currently receiving cholesterol-lowering medication. Few clinical trials in recent years have studied patients who have not yet had a cardiac event.<\/p>\n\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\"><strong><mark style=\"color:#0b5d8c\" class=\"has-inline-color\">High LDL cholesterol<\/mark><\/strong> <mark style=\"color:#0b5d8c\" class=\"has-inline-color\">can build up in the walls of blood vessels, creating blockages and increasing the risk of heart attack or stroke. <strong>Statins<\/strong> are the standard first-line treatment for preventing cardiovascular disease and work by lowering blood cholesterol levels.<\/mark> However, some patients struggle with adverse side effects, particularly muscle pain or weakness, that prevent them from using statins at recommended doses. <strong><mark style=\"color:#0b5d8c\" class=\"has-inline-color\">Bempedoic acid<\/mark><\/strong> differs from statins in that it is not activated until it reaches the liver, which limits the drug&#8217;s potential to cause adverse effects in muscle.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.--1024x972.jpg\" alt=\"Dr. Steven Nissen\" class=\"wp-image-8191\" width=\"284\" height=\"270\" srcset=\"https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.--1024x972.jpg 1024w, https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.--300x285.jpg 300w, https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.--768x729.jpg 768w, https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.--1536x1458.jpg 1536w, https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.--2048x1944.jpg 2048w\" sizes=\"auto, (max-width: 284px) 100vw, 284px\" \/><figcaption class=\"wp-element-caption\">Dr. Steven Nissen<\/figcaption><\/figure>\n<\/div>\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\"><mark style=\"color:#0b5d8c\" class=\"has-inline-color\">Adverse effects seen with <strong>bempedoic acid<\/strong> included a higher incidence of gout and gallstones.<\/mark><\/p>\n\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\"><mark style=\"color:#0b5d8c\" class=\"has-inline-color\">The study was funded by <em><strong>Esperion Therapeutics<\/strong><\/em>, the developer of <strong>bempedoic acid<\/strong>.<\/mark><\/p>\n\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\"><strong><mark style=\"color:#0b5d8c\" class=\"has-inline-color\">Dr. Nissen<\/mark><\/strong> has served as a consultant for many pharmaceutical companies and has overseen clinical trials for AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Novartis, Mineralys, Silence Therapeutics and Pfizer. However, he does not accept fees for services or other compensation from commercial entities.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"47\" src=\"https:\/\/afcomunicacion.com\/wp-content\/uploads\/2022\/03\/Cleveland_Clinic_logo_color-300x47.png\" alt=\"\"><\/p>\n\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\"><strong>About Cleveland Clinic<\/strong><\/p>\n\n\n\n<p class=\"has-text-align-justify has-black-color has-text-color wp-block-paragraph\"><strong><mark style=\"color:#138c00\" class=\"has-inline-color\">Cleveland Clinic<\/mark><\/strong> is a nonprofit multispecialty academic medical centre that integrates clinical and hospital care with research and education. Located in <strong><mark style=\"color:#138c00\" class=\"has-inline-color\">Cleveland<\/mark><\/strong>, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based on the principles of cooperation, compassion and innovation. <strong><mark style=\"color:#138c00\" class=\"has-inline-color\">Cleveland Clinic<\/mark><\/strong> has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. &nbsp;<\/p>\n\n\n\n<p class=\"has-text-align-justify has-black-color has-text-color wp-block-paragraph\"><em>U.S. News &amp; World Report<\/em> consistently names <strong><mark style=\"color:#138c00\" class=\"has-inline-color\">Cleveland Clinic<\/mark><\/strong> as one of the nation&#8217;s best hospitals in its annual &#8220;America&#8217;s Best Hospitals&#8221; survey. Among <strong><mark style=\"color:#138c00\" class=\"has-inline-color\">Cleveland Clinic&#8217;s<\/mark><\/strong> 72,500 employees worldwide are more than 5,050 salaried physicians and researchers, and 17,800 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. &nbsp;<strong><mark style=\"color:#138c00\" class=\"has-inline-color\">Cleveland Clinic<\/mark><\/strong> is a 6,500-bed health system that includes a 173-acre main campus near downtown Cleveland, 21 hospitals, more than 220 outpatient facilities, and locations in northeast Ohio; southeast Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. <\/p>\n\n\n\n<p class=\"has-text-align-justify has-black-color has-text-color wp-block-paragraph\">In 2021, there were 10.2 million outpatient visits, 304,000 hospital admissions and observations, and 259,000 surgeries across <strong><mark style=\"color:#138c00\" class=\"has-inline-color\">Cleveland Clinic&#8217;s<\/mark><\/strong> health system. Patients came for treatment from every state and 185 countries. &nbsp;<\/p>\n\n\n\n<p class=\"has-text-align-justify has-black-color has-text-color wp-block-paragraph\">Visit us at <mark style=\"color:#138c00\" class=\"has-inline-color\"><span style=\"text-decoration: underline\">clevelandclinic.org<\/span><\/mark>. Follow us at twitter.com\/<mark style=\"color:#138c00\" class=\"has-inline-color\"><span style=\"text-decoration: underline\">ClevelandClinic<\/span><\/mark>. News and resources available at<mark style=\"color:#138c00\" class=\"has-inline-color\"><span style=\"text-decoration: underline\"> newsroom.clevelandclinic.org<\/span><\/mark>.<\/p>\n\n\n\n<p class=\"has-black-color has-text-color wp-block-paragraph\"><em>Find out more about <mark><a href=\"https:\/\/afcomunicacion.com\/nosotros\/\"><mark style=\"background-color:#ffffff;color:#0b5d8c\" class=\"has-inline-color\"><span style=\"text-decoration: underline\">AF Comunicaci\u00f3n Estrat\u00e9gica<\/span><\/mark><\/a><mark style=\"background-color:#ffffff\" class=\"has-inline-color\"><a href=\"https:\/\/afcomunicacion.com\/nosotros\/\"> <\/a>and&nbsp;<\/mark><a href=\"https:\/\/afcomunicacion.com\/nuestros-clientes\/\"><mark style=\"background-color:#ffffff;color:#0b5d8c\" class=\"has-inline-color\"><span style=\"text-decoration: underline\">its clients<\/span><\/mark><\/a><\/mark><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Findings from a clinical trial led by Cleveland Clinic showed that the use of bempedoic acid (a cholesterol-lowering drug) in statin-intolerant patients who have not yet had a cardiovascular event but have risk factors such as diabetes significantly reduced the chance of death from heart disease and other major adverse cardiovascular events, such as heart [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":8191,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[485,486],"tags":[3095,3096,3097,3098,3099,3100,3101],"class_list":["post-12893","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog-en","category-press-room","tag-acido-bempedoico-en","tag-clear-outcomes-en","tag-colesterol-en","tag-colesterol-ldl-en","tag-esperion-therapeutics-en","tag-estatinas-en","tag-revista-de-la-asociacion-medica-americana-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cleveland Clinic-led trial shows cholesterol-lowering drug reduces cardiac events, including death, in statin-intolerant patients at high cardiovascular risk - AF Comunicaci\u00f3n Estrat\u00e9gica<\/title>\n<meta name=\"description\" content=\"Statins are the standard first-line treatment for preventing cardiovascular disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cleveland Clinic-led trial shows cholesterol-lowering drug reduces cardiac events, including death, in statin-intolerant patients at high cardiovascular risk\" \/>\n<meta property=\"og:description\" content=\"Statins are the standard first-line treatment for preventing cardiovascular disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/\" \/>\n<meta property=\"og:site_name\" content=\"AF Comunicaci\u00f3n Estrat\u00e9gica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/afcomunicacionestrategica\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-06T19:39:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.-.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2107\" \/>\n\t<meta property=\"og:image:height\" content=\"2000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"AF Comunicaci\u00f3n Estrat\u00e9gica\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AFComunicacion\" \/>\n<meta name=\"twitter:site\" content=\"@AFComunicacion\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"AF Comunicaci\u00f3n Estrat\u00e9gica\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/blog-en\\\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/blog-en\\\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\\\/\"},\"author\":{\"name\":\"AF Comunicaci\u00f3n Estrat\u00e9gica\",\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/#\\\/schema\\\/person\\\/fe64955688913b2174ea1635745e7379\"},\"headline\":\"Cleveland Clinic-led trial shows cholesterol-lowering drug reduces cardiac events, including death, in statin-intolerant patients at high cardiovascular risk\",\"datePublished\":\"2023-07-06T19:39:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/blog-en\\\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\\\/\"},\"wordCount\":712,\"publisher\":{\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/blog-en\\\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/afcomunicacion.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.-.jpg\",\"keywords\":[\"\u00e1cido bempedoico\",\"CLEAR Outcomes\",\"colesterol\",\"colesterol LDL\",\"Esperion Therapeutics\",\"estatinas\",\"Revista de la Asociaci\u00f3n M\u00e9dica Americana\"],\"articleSection\":[\"Blog\",\"Press Room\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/blog-en\\\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\\\/\",\"url\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/blog-en\\\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\\\/\",\"name\":\"Cleveland Clinic-led trial shows cholesterol-lowering drug reduces cardiac events, including death, in statin-intolerant patients at high cardiovascular risk - AF Comunicaci\u00f3n Estrat\u00e9gica\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/blog-en\\\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/blog-en\\\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/afcomunicacion.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.-.jpg\",\"datePublished\":\"2023-07-06T19:39:22+00:00\",\"description\":\"Statins are the standard first-line treatment for preventing cardiovascular disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/blog-en\\\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/blog-en\\\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/blog-en\\\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\\\/#primaryimage\",\"url\":\"https:\\\/\\\/afcomunicacion.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.-.jpg\",\"contentUrl\":\"https:\\\/\\\/afcomunicacion.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.-.jpg\",\"width\":2107,\"height\":2000,\"caption\":\"Doctor Steven Nissen, director acad\u00e9mico del Instituto Vascular y Tor\u00e1cico de Cleveland Clinic.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/blog-en\\\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cleveland Clinic-led trial shows cholesterol-lowering drug reduces cardiac events, including death, in statin-intolerant patients at high cardiovascular risk\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/\",\"name\":\"AF Comunicaci\u00f3n Estrat\u00e9gica\",\"description\":\"Agencia especializada en consultor\u00eda de Comunicaci\u00f3n Estrat\u00e9gica, Relaciones P\u00fablicas y Eventos Corporativos.\",\"publisher\":{\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/#organization\",\"name\":\"AF Comunicaci\u00f3n Estrat\u00e9gica\",\"url\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"AF Comunicaci\u00f3n Estrat\u00e9gica\"},\"image\":{\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/afcomunicacionestrategica\",\"https:\\\/\\\/x.com\\\/AFComunicacion\",\"https:\\\/\\\/www.instagram.com\\\/afcomunicacion\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/afcomunicacion\\\/?viewAsMember=true\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCb0JkclVAyd3M9SzeiiNJAg\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/#\\\/schema\\\/person\\\/fe64955688913b2174ea1635745e7379\",\"name\":\"AF Comunicaci\u00f3n Estrat\u00e9gica\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/85f2cc1a31c5a2575f1b79ad47644a448b6cdfff59769f0219f7f09f29871d9e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/85f2cc1a31c5a2575f1b79ad47644a448b6cdfff59769f0219f7f09f29871d9e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/85f2cc1a31c5a2575f1b79ad47644a448b6cdfff59769f0219f7f09f29871d9e?s=96&d=mm&r=g\",\"caption\":\"AF Comunicaci\u00f3n Estrat\u00e9gica\"},\"url\":\"https:\\\/\\\/afcomunicacion.com\\\/en\\\/author\\\/dgonzalez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cleveland Clinic-led trial shows cholesterol-lowering drug reduces cardiac events, including death, in statin-intolerant patients at high cardiovascular risk - AF Comunicaci\u00f3n Estrat\u00e9gica","description":"Statins are the standard first-line treatment for preventing cardiovascular disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/","og_locale":"en_US","og_type":"article","og_title":"Cleveland Clinic-led trial shows cholesterol-lowering drug reduces cardiac events, including death, in statin-intolerant patients at high cardiovascular risk","og_description":"Statins are the standard first-line treatment for preventing cardiovascular disease.","og_url":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/","og_site_name":"AF Comunicaci\u00f3n Estrat\u00e9gica","article_publisher":"https:\/\/www.facebook.com\/afcomunicacionestrategica","article_published_time":"2023-07-06T19:39:22+00:00","og_image":[{"width":2107,"height":2000,"url":"https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.-.jpg","type":"image\/jpeg"}],"author":"AF Comunicaci\u00f3n Estrat\u00e9gica","twitter_card":"summary_large_image","twitter_creator":"@AFComunicacion","twitter_site":"@AFComunicacion","twitter_misc":{"Written by":"AF Comunicaci\u00f3n Estrat\u00e9gica","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/#article","isPartOf":{"@id":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/"},"author":{"name":"AF Comunicaci\u00f3n Estrat\u00e9gica","@id":"https:\/\/afcomunicacion.com\/en\/#\/schema\/person\/fe64955688913b2174ea1635745e7379"},"headline":"Cleveland Clinic-led trial shows cholesterol-lowering drug reduces cardiac events, including death, in statin-intolerant patients at high cardiovascular risk","datePublished":"2023-07-06T19:39:22+00:00","mainEntityOfPage":{"@id":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/"},"wordCount":712,"publisher":{"@id":"https:\/\/afcomunicacion.com\/en\/#organization"},"image":{"@id":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/#primaryimage"},"thumbnailUrl":"https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.-.jpg","keywords":["\u00e1cido bempedoico","CLEAR Outcomes","colesterol","colesterol LDL","Esperion Therapeutics","estatinas","Revista de la Asociaci\u00f3n M\u00e9dica Americana"],"articleSection":["Blog","Press Room"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/","url":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/","name":"Cleveland Clinic-led trial shows cholesterol-lowering drug reduces cardiac events, including death, in statin-intolerant patients at high cardiovascular risk - AF Comunicaci\u00f3n Estrat\u00e9gica","isPartOf":{"@id":"https:\/\/afcomunicacion.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/#primaryimage"},"image":{"@id":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/#primaryimage"},"thumbnailUrl":"https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.-.jpg","datePublished":"2023-07-06T19:39:22+00:00","description":"Statins are the standard first-line treatment for preventing cardiovascular disease.","breadcrumb":{"@id":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/#primaryimage","url":"https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.-.jpg","contentUrl":"https:\/\/afcomunicacion.com\/wp-content\/uploads\/2023\/07\/Doctor-Steven-Nissen-director-academico-del-Instituto-Vascular-y-Toracico-de-Cleveland-Clinic.-.jpg","width":2107,"height":2000,"caption":"Doctor Steven Nissen, director acad\u00e9mico del Instituto Vascular y Tor\u00e1cico de Cleveland Clinic."},{"@type":"BreadcrumbList","@id":"https:\/\/afcomunicacion.com\/en\/blog-en\/cleveland-clinic-led-trial-shows-cholesterol-lowering-drug-reduces-cardiac-events-in-statin-intolerant-patients-at-high-risk\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/afcomunicacion.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cleveland Clinic-led trial shows cholesterol-lowering drug reduces cardiac events, including death, in statin-intolerant patients at high cardiovascular risk"}]},{"@type":"WebSite","@id":"https:\/\/afcomunicacion.com\/en\/#website","url":"https:\/\/afcomunicacion.com\/en\/","name":"AF Comunicaci\u00f3n Estrat\u00e9gica","description":"Agencia especializada en consultor\u00eda de Comunicaci\u00f3n Estrat\u00e9gica, Relaciones P\u00fablicas y Eventos Corporativos.","publisher":{"@id":"https:\/\/afcomunicacion.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/afcomunicacion.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/afcomunicacion.com\/en\/#organization","name":"AF Comunicaci\u00f3n Estrat\u00e9gica","url":"https:\/\/afcomunicacion.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/afcomunicacion.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"AF Comunicaci\u00f3n Estrat\u00e9gica"},"image":{"@id":"https:\/\/afcomunicacion.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/afcomunicacionestrategica","https:\/\/x.com\/AFComunicacion","https:\/\/www.instagram.com\/afcomunicacion\/","https:\/\/www.linkedin.com\/company\/afcomunicacion\/?viewAsMember=true","https:\/\/www.youtube.com\/channel\/UCb0JkclVAyd3M9SzeiiNJAg"]},{"@type":"Person","@id":"https:\/\/afcomunicacion.com\/en\/#\/schema\/person\/fe64955688913b2174ea1635745e7379","name":"AF Comunicaci\u00f3n Estrat\u00e9gica","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/85f2cc1a31c5a2575f1b79ad47644a448b6cdfff59769f0219f7f09f29871d9e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/85f2cc1a31c5a2575f1b79ad47644a448b6cdfff59769f0219f7f09f29871d9e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/85f2cc1a31c5a2575f1b79ad47644a448b6cdfff59769f0219f7f09f29871d9e?s=96&d=mm&r=g","caption":"AF Comunicaci\u00f3n Estrat\u00e9gica"},"url":"https:\/\/afcomunicacion.com\/en\/author\/dgonzalez\/"}]}},"_links":{"self":[{"href":"https:\/\/afcomunicacion.com\/en\/wp-json\/wp\/v2\/posts\/12893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/afcomunicacion.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/afcomunicacion.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/afcomunicacion.com\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/afcomunicacion.com\/en\/wp-json\/wp\/v2\/comments?post=12893"}],"version-history":[{"count":0,"href":"https:\/\/afcomunicacion.com\/en\/wp-json\/wp\/v2\/posts\/12893\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/afcomunicacion.com\/en\/wp-json\/wp\/v2\/media\/8191"}],"wp:attachment":[{"href":"https:\/\/afcomunicacion.com\/en\/wp-json\/wp\/v2\/media?parent=12893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/afcomunicacion.com\/en\/wp-json\/wp\/v2\/categories?post=12893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/afcomunicacion.com\/en\/wp-json\/wp\/v2\/tags?post=12893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}